Status:
COMPLETED
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Lead Sponsor:
Constellation Pharmaceuticals
Conditions:
Advanced Malignancies
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies
Eligibility Criteria
Inclusion
- 18 years of age or older
- Confirmed diagnosis of an advanced malignancy for which no effective standard treatment options are available
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
Exclusion
- Chronic or active conditions and/or concomitant medication use that would prohibit treatment
Key Trial Info
Start Date :
July 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 29 2024
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05391022
Start Date
July 20 2021
End Date
February 29 2024
Last Update
July 28 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Gabrail Cancer Center Research
Canton, Ohio, United States, 44718
2
Gettysburg Cancer Center
Gettysburg, Pennsylvania, United States, 17325
3
Start Mountain Region
West Valley City, Utah, United States, 84119
4
Hight Technology Hospital Medcenter
Batumi, Georgia